Short-term treatment (6 weeks) with 10 mg prednisolone effectively reduces finger pain and improves function in patients who have painful hand osteoarthritis (OA) coupled with signs of inflammation, the HOPE* study has shown.
The biologic disease-modifying antirheumatic drug (bDMARD) tocilizumab (TCZ), used alone or with concomitant conventional synthetic (cs) DMARDs, is an adequate alternative to a TNFi*-csDMARD regimen in patients with rheumatoid arthritis (RA), results from the TOCERRA** initiative show.
Post hoc results of the phase II FORWARD* study continued to reflect positive structural changes with the recombinant human fibroblast growth factor(FGF)-18 sprifermin, given the substantial dose-dependent increases in cartilage thickness gain and reductions in cartilage loss independent of location in the femorotibial joints (FTJ) of patients with knee osteoarthritis (OA).
Ixekizumab induces early and durable improvements in psoriatic arthritis (PsA) patients naïve to biological disease-modifying antirheumatic drugs (bDMARDs), with response occurring as early as week 1 and persisting throughout 3 years of treatment without incremental safety risks, according to the results of the phase III SPIRIT-P1* trial.
The high-affinity monoclonal antibody ixekizumab was superior to the tumour necrosis factor inhibitor adalimumab in the achievement of simultaneous improvements in joint and skin disease among bDMARD*-naïve patients with active psoriatic arthritis (PsA) and inadequate response to conventional synthetic(cs)DMARDs, according to the 24-week results of the SPIRIT-H2H study.
A recent study reports a mean growth rate of proximal aorta of about 0.1 mm/year in hypertensive patients with known aortic dilatation. In addition, those with increased rather than normal aortic z score have slower dilatation over time.
Among patients with nonvalvular atrial fibrillation (AF), treatment with apixaban was associated with a lower rate of ischaemic stroke, systemic embolism, and major bleeding compared with rivaroxaban, according to a large study assessing patients in routine care.